Swiss Healthcare Takes Step Towards Digitalisation

robot
Abstract generation in progress

(MENAFN- Swissinfo) On Thursday, the Swiss House of Representatives voted 128 to 62 in favour of a revision of the Therapeutic Products Act that would require digital prescriptions and medication plans. The goal is to improve patient safety. Select your language

Generated with artificial intelligence. Listening: Swiss healthcare takes step towards digitalisation This content was published on March 12, 2026 - 14:44 1 minute Keystone-SDA

Français fr Le système de santé fait un nouveau pas vers le numérique Original Read more: Le système de santé fait un nouveau pas vers le numé

** + Get the most important news from Switzerland in your inbox

The revision should enable the law to keep pace with developments in medicine to ensure patient safety. The prescribing, dispensing and use of medicines can give rise to misunderstandings and errors that put patients at risk.

In future, prescriptions and medication plans will be provided in digital form. This will enable them to be read unambiguously and transmitted digitally.

“Progress in digitalisation in this area will significantly improve patient safety,” said Patrick Hässig from the Liberal Green party.

Translated from French by AI/jdp

We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.

Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.

If you have any questions about how we work, write to us at …

External Content Related Stories Popular Stories N

In compliance with the JTI standards

More: SWI swissinfo certified by the Journalism Trust Initiati

You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at …

**

MENAFN12032026000210011054ID1110854017

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments